Company news
Pharmadrug, Inc. (CSE:PHRX) news
Every Pharmadrug, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
PharmaDrug Completes Acquisition of Initial 19.9% Interest in Canurta Inc. and Completes Debt Restructuring
January 5, 2026
PharmaDrug Announces Debt Restructuring
October 31, 2025
PharmaDrug Signs Definitive Agreement to Acquire Equity Interest in Canurta Inc
October 30, 2025
PharmaDrug Inc.: Correction to News Release Dated July 30, 2025
July 30, 2025
PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.
July 30, 2025
PharmaDrug Announces Resignation of Rob Steen as CEO and From Board of Directors
June 16, 2025
PharmaDrug Announces Strategic Review Process Intended to Maximize Shareholder Value
June 6, 2025
PharmaDrug Announces Issuance of Debenture Units
November 15, 2024
PharmaDrug Announces Proposed Issuance of Debenture Units
October 31, 2024
PharmaDrug's Sairiyo Therapeutics Announces Successful Completion of Stability Study of PD-001 (Patented Reformulated Cepharanthine) to S...
October 31, 2024
PharmaDrug's Sairiyo Therapuetics Announces Initiation of Study Start-Up Activities and Design for Clinical Trial of PD-001 (Patented Ref...
September 19, 2024
PharmaDrug's Sairiyo Therapuetics Announces Independent Screening Identifying Cepharanthine's Potential to Bind to Monkeypox (Mpox) Proteins
August 21, 2024
PharmaDrug's Sairiyo Therapuetics Receives Approval to Initiate Phase 1 Clinical Trial of Patented Reformulated Cepharanthine
August 19, 2024
Pharmadrug's Securedose Announces LOI with Canadian Controlled Drug Substance Licensed Dealer for Patent Pending Pharmaceutical Grade Coc...
May 23, 2024
PharmaDrug's Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
May 15, 2024
PharmaDrug Provides Forward Plan to Move Its Patent Pending Process and Formulation of Pharmaceutical Grade Biosynthetic Cocaine Through ...
May 13, 2024
PharmaDrug Announces Director Appointment and Resignation
May 2, 2024
PharmaDrug's Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
May 1, 2024
PharmaDrug's SecureDose Announces the Advancement of Process Development of Its Biosynthetic Formulation of Pharmaceutical Grade Cocaine
April 16, 2024
PharmaDrug's SecureDose Announces Filing of US Provisional Patent for Manufacturing Method for Biosynthetic Pharmaceutical Grade Cocaine
March 13, 2024
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman
February 27, 2024
PharmaDrug's Sairiyo Successfully Demonstrates Ability to Manufacture Cepharanthine (PD-001) for Human Clinical Studies
February 14, 2024
PharmaDrug Inc. Engages Investor Relations and Marketing Service Providers
February 12, 2024
PharmaDrug Inc. Announces Successful Closing of Non-Brokered Private Placement
February 8, 2024
PharmaDrug Inc. Announces Proposed Non-Brokered Private Placement
February 1, 2024
PharmaDrug CEO Provides Vision for Securedose Acquisition
December 13, 2023
PharmaDrug Inc. Completes Debt Restructuring
November 15, 2023
PharmaDrug Inc. Announces Grant of Stock Options
November 8, 2023
PharmaDrug Inc. Closes Acqusition of Securedose Synthetics
November 7, 2023
PharmaDrug Inc. Enters Definitive Agreement to Acquire SecureDose Synthetics
October 27, 2023
PharmaDrug Announces Share Consolidation and Change to Chief Financial Officer
October 20, 2023
PharmaDrug Announces Amendment to Shareholder Meeting Matter
September 19, 2023
PharmaDrug Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease
September 14, 2023
PharmaDrug Announces Appointment of CEO and Changes to the Board of Directors
September 6, 2023
PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.
July 18, 2023
PharmaDrug Announces Termination of General Security Agreement and Issuance of Common Shares
July 5, 2023
PharmaDrug Brings On Advisor to Maximize Shareholder Value With Its Underlying Assets
May 23, 2023
PharmaDrug Announces Cease Trade Order
May 8, 2023
PharmaDrug Announces Non-Brokered Offering of $100,000 of Convertible Secured Debentures
April 14, 2023
PharmaDrug Collaborates with PharmaTher for Development of DMT Transdermal Patch
February 22, 2023
PharmaDrug Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer
February 13, 2023
PharmaDrug Advances Programs in Oncology with Filing of PCT Application Detailing the Use of PD-001 for Treatment of Prostate Cancer
January 31, 2023